Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1018-1024 , July 2010

Favorable Outcome in Patients with Acute Myelogenous Leukemia with the Nucleophosmin Gene Mutation Autografted after Conditioning with High-Dose Continuous Infusion of Idarubicin and Busulfan

  • Felicetto Ferrara

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • Corresponding Author InformationCorrespondence and reprint requests: Felicetto Ferrara, MD, Via Nicolò Piccinni 6, 80128 Napoli, Italy.
    • ,
  • Tiziana Izzo

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Clelia Criscuolo

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Cira Riccardi

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Giada Muccioli

      Affiliations

    • CEINGE, Federico II University, Naples, Italy
    • ,
  • Assunta Viola

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Fabrizio Pane

      Affiliations

    • CEINGE, Federico II University, Naples, Italy
    • ,
  • Salvatore Palmieri

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy

Received 5 January 2010 ,Accepted 13 February 2010.

  • Image Result

    OS and DSF for the whole patient population (median: 34 and 22 months, respectively).

    OS and DSF for the whole patient population (median: 34 and 22 months, respectively).

  • Image Result

    OS and DFS of patients with NPM1 isolated mutations as opposed to controls: median OS and DFS were significantly longer for patients with isolated NPM1 mutation as opposed to controls (OS: not reached

    OS and DFS of patients with NPM1 isolated mutations as opposed to controls: median OS and DFS were significantly longer for patients with isolated NPM1 mutation as opposed to controls (OS: not reached versus 25 months, P = .02; DFS: not reached versus 16 months, P = .007, respectively).

  • Image Result
    OS and DFS of patients with NPM1 isolated mutations as opposed to patients with NPM1+/FLT3+ AML (median OS not reached versus 27 months, P = .03; DFS not reached versus 16 months, P = .004).

    OS and DFS of patients with NPM1 isolated mutations as opposed to patients with NPM1+/FLT3+ AML (median OS not reached versus 27 months, P = .03; DFS not reached versus 16 months, P = .004).

 Financial disclosure: See Acknowledgments on page 1023.

PII: S1083-8791(10)00082-0

doi: 10.1016/j.bbmt.2010.02.011

Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1018-1024 , July 2010

Article Tools

* Image Usage & Resolution